October 3, 2022
New smart soft contact lens technology developed by a multidisciplinary team of engineers and health care researchers at Purdue University and Indiana University School of Optometry looks to gather important intraocular pressure measurements for 24-hour cycles as a way to detect glaucoma.
September 30, 2022
A new study recently published Trends in Cardiovascular Medicine reveals that consuming high intakes of refined grain foods does not increase one’s risk of cardiovascular disease (CVD), coronary heart disease, heart attack, heart failure, or stroke. The study also calls for reflection on the Western dietary pattern and its consideration in future dietary recommendations.
September 30, 2022
Every year, a series of athletic games connects the Boilermaker community’s love for football, basketball and finding a cure for cancer. The Hammer Down Cancer games raise money for and awareness of the Purdue Center for Cancer Research.
Gold and Black LIVE Sept 30 Special Guest: Robbie Hummel, E’Twaun Moore and Dr. Andy Mesecar
September 27, 2022
The study of lipids and membranes remains a critical and emerging area for cutting-edge research — one that has great potential to impact human health and the understanding and treatment of diseases. Our symposia at Discover BMB, the annual meeting of the American Society for Biochemistry and Molecular Biology, in Seattle in March will bring together leading investigators in lipid metabolism and membrane function in replication of microorganisms and viruses, communicate novel protein structural information in lipid metabolism and transport, and promote the understanding of membrane structure and biophysics in cell physiology.
September 26, 2022
Three Indiana institutions are teaming up to try to develop a treatment for glioblastoma, a lethal cancer that begins with the brain or spinal cord, and is difficult to treat, often requiring a combination of surgery, chemotherapy and radiation. The project won a one-year, $398,314 grant from the National Cancer Institute, according to a news release Thursday from Purdue University. Monon Bioventures LLC, a privately held company that helps scientists navigate the early-stage challenges of translating their research into the clinic, was awarded the funding. The other partners are the Purdue Research Foundation, the research arm of Purdue University; and Genezen, an Indianapolis-based contract development and manufacturing organization The money is designed to help demonstrate the feasibility of manufacturing a glioblastoma therapeutic created at Purdue University College of Pharmacy.
Purdue project to develop treatment for deadly brain cancer wins $398,000 in federal funding
September 22, 2022
Funds from a National Cancer Institute grant will be used to demonstrate the feasibility of manufacturing a glioblastoma therapeutic created at the Purdue University College of Pharmacy. Monon Bioventures, which received the grant, will team with Purdue inventor Sandro Matosevic and Genezen on the project.
Monon Bioventures receives nearly $400,000 to develop Purdue-discovered glioblastoma treatment
September 22, 2022
Indianapolis-based Monon Bioventures LLC has received a one-year, nearly $400,000 grant from the National Cancer Institute to demonstrate the feasibility of manufacturing a glioblastoma therapeutic created at the Purdue University College of Pharmacy. Glioblastoma is an aggressive type of cancer that can occur in the brain or spinal cord. “It grows, multiplies and spreads quickly, is almost always lethal, and there is no effective cure. New, effective therapies are desperately needed,” said Sandro Matosevic, assistant professor in the Department of Industrial and Physical Pharmacy, who has developed a potential treatment.
Purdue researcher pursuing treatment for aggressive form of brain cancer
September 15, 2022
In order to answer this critical question, a dedicated session will be organized during the 9th Annual Meeting of the International Society of Microbiota, taking place on 19-21 October 2022 at Sorbonne University in Paris, France and Online. Targeting Microbiota 2022 will put together many complementary topics, controversies and clinical advances – from oral microbiota, to gut microbiota as well as vaginal microbiota.
September 14, 2022
The National Science Foundation has awarded WaveLogix, a nascent technology company, a six-month, $255,996 SBIR Phase I grant to further its technology. WaveLogix is commercializing an Internet of Things sensing system for infrastructure monitoring.
September 14, 2022
West Lafayette-based technology startup WaveLogix has been awarded a more than $255,000 grant from the National Science Foundation to develop its infrastructure technology. The startup, which is commercializing an Internet of Things sensing system for concrete strength monitoring, says the six-month Small Business Innovation Research Phase I grant will help accelerate its timeline to market. “The funding will help the company accelerate the product development phase, particularly the IoT platform for data processing and sharing,” said Luna Lu, founder and chief science officer at WaveLogix. Lu, who invented the technology being commercialized by WaveLogix, is also a professor at the Lyles School of Civil Engineering at Purdue University, as well as the founding director of the Center for Intelligent Infrastructure at Purdue.
WaveLogix receives grant to commercialize its infrastructure monitoring tech
